Abstract
Numerous clinical evidences support the notion that glial changes in fronto-limbic brain areas could contribute to the pathophysiology of mood disorders. Glial alterations have been reported not only in patients, but also in various kinds of animal models for depression. Molecular and cellular data suggest that all the major classes of glial cells are affected in these conditions, including astrocytes, oligodendrocytes, NG2-positive cells and microglia. The aim of this review was to summarize the currently available experimental results demonstrating alterations in glial morphology and functioning in animal models for mood disorders. Better understanding of these glial changes affecting neuronal activity could help us to identify novel targets for the development of antidepressant drugs.
Keywords: Astrocyte, adult neurogenesis, depression, hippocampus, microglia, oligodendrocyte.
Current Drug Targets
Title:Altered Glial Plasticity in Animal Models for Mood Disorders
Volume: 14 Issue: 11
Author(s): Boldizsár Czéh, Eberhard Fuchs and Gabriele Flügge
Affiliation:
Keywords: Astrocyte, adult neurogenesis, depression, hippocampus, microglia, oligodendrocyte.
Abstract: Numerous clinical evidences support the notion that glial changes in fronto-limbic brain areas could contribute to the pathophysiology of mood disorders. Glial alterations have been reported not only in patients, but also in various kinds of animal models for depression. Molecular and cellular data suggest that all the major classes of glial cells are affected in these conditions, including astrocytes, oligodendrocytes, NG2-positive cells and microglia. The aim of this review was to summarize the currently available experimental results demonstrating alterations in glial morphology and functioning in animal models for mood disorders. Better understanding of these glial changes affecting neuronal activity could help us to identify novel targets for the development of antidepressant drugs.
Export Options
About this article
Cite this article as:
Czéh Boldizsár, Fuchs Eberhard and Flügge Gabriele, Altered Glial Plasticity in Animal Models for Mood Disorders, Current Drug Targets 2013; 14 (11) . https://dx.doi.org/10.2174/1389450111314110005
DOI https://dx.doi.org/10.2174/1389450111314110005 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Mechanisms of Gastric Mucosal Injury: Focus on Microvascular Endothelium as a Key Target
Current Medicinal Chemistry Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets CT and MR Imaging of the Encephalopathic Child
Current Medical Imaging Between Bench and Bed Side: PI3K Inhibitors
Current Molecular Pharmacology Extrasynaptic GABA<sub>A</sub> Receptors in the Brainstem and Spinal Cord: Structure and Function
Current Pharmaceutical Design Plasma Level of D-dimer is an Independent Diagnostic Biomarker for Deep Venous Thrombosis in Patients with Ischemic Stroke
Current Neurovascular Research Biological Activities of QIAPI 1 as a Melanin Precursor and Its Therapeutic Effects in Wistar Rats Exposed to Arsenic Poisoning
Central Nervous System Agents in Medicinal Chemistry A Novel Treatment Strategy for Sepsis and Septic Shock Based on the Interactions between Prostanoids, Nitric Oxide, and 20-Hydroxyeicosatetraenoic Acid
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Heme Oxygenase-1/Carbon Monoxide: Novel Therapeutic Strategies in Critical Care Medicine
Current Drug Targets Synthetic Cannabinoids as Drugs of Abuse
Current Drug Abuse Reviews Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Cyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders
Current Pharmaceutical Design Ischemic Neuronal Damage
Current Pharmaceutical Design New Patents on Topical Anesthetics
Recent Patents on Inflammation & Allergy Drug Discovery Towards a Causal Model for Disgust in the Anxiety Disorders: An Integration of Evidence from Neuroscience
Current Psychiatry Reviews Levosimendan Reduces Prostaglandin F2a-dependent Vasoconstriction in Physiological Vessels and After Experimentally Induced Subarachnoid Hemorrhage
Current Neurovascular Research Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk
Current Alzheimer Research The Extra-Hematopoietic Role of Erythropoietin in Diabetes Mellitus
Current Diabetes Reviews HIV-1 Tat Disrupts CX3CL1-CX3CR1 Axis in Microglia via the NF-κBYY1 Pathway
Current HIV Research Neurophysiology and Treatment of Disorders of Consciousness Induced by Traumatic Brain Injury: Orexin Signaling as a Potential Therapeutic Target
Current Pharmaceutical Design